Hua Medicine
IPOGlobal innovation in diabetes care.
- Headquarters
- Shanghai
- Employees
- 51–200
- Founded
- 2010
- Business Model
- B2B
- Website
- huamedicine.com
- Total Funding
- $212.5M
- Last Round
- $117.4M Series DMar 2018
- Rounds
- 4
- Type
- Public
About
Hua Medicine is a clinical-stage biotech company focused on innovative therapies for type 2 diabetes and CNS disorders. Its lead product, HuaTangNing (dorzagliatin), a first-in-class glucokinase activator, was approved in China in 2022 for T2D patients, including those with renal impairment.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Investors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Biopharmaceutical services company
Specialty pharmaceutical company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...